Purpose
To assess potential differences in genetic counseling (GC) services delivered by board certified genetic healthcare providers (GHPs) versus non-GHPs, we evaluated: 1) patient recall and content of pre-test GC for hereditary breast and ovarian cancer; and 2) whether full BRCA1 and 2 gene sequencing was performed when less expensive single-site or Ashkenazi Jewish (AJ) founder mutation testing may be sufficient.
Methods
Participants completed a questionnaire and provided BRCA test reports that included testing provider and type of test. Chi-square tests and logistic regression were used for analysis.
Results
Of 473 participants, >90% were White, female, and BRCA mutation carriers. Of the 276 (58%) with GHP involvement, 97% recalled a pre-test discussion compared to 59% without GHP involvement (p<0.001). Among the subgroup who recalled a pretest discussion (n=385), those with GHP involvement indicated higher adherence to eight recognized GC elements; 4 were statistically significant. Furthermore, involvement of a GHP halved the likelihood that comprehensive BRCA testing was ordered among the 266 for whom single site or multisite-3 testing may have been sufficient (p=0.02).
Conclusion
Our results suggest that GHP involvement is associated with adherence to nationally recommended GC practices and could potentially reduce costs of BRCA genetic testing.